===
EQS-News: Biotest AG / Key word(s): Sustainability
Biotest's sustainability campaign GoFuture part of the new documentary 'Future Seeds'
2024-06-24 / 14:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

PRESS RELEASE


Biotest's sustainability campaign GoFuture part of the new documentary "Future Seeds"

. Documentary shows sustainable projects from around the world and the eco-art mural "Linfa" on the Biotest
campus
. Film addresses socially relevant topic of eco-anxiety among young people
. Now available on Prime Video in twelve countries

Dreieich, Germany, 24 June 2024. With its GoFuture sustainability campaign and its gigantic mural on the campus in
Dreieich, Biotest AG has taken the first step with a visible signal of its growing commitment to more sustainability
last year. The new documentary film "Future Seeds" now picks up on this extraordinary project and recently celebrated
its premiere on Prime Video.
Future Seeds is a documentary film about innovative ideas and projects for a more sustainable future, embedded in a
socially relevant and moving narrative. The film addresses the now widespread phenomenon of eco-anxiety, which
manifests itself in extreme sadness, anger and despair, particularly among young people. In the film, a teenager is
psychologically burdened by her fear of the consequences of climate change and is in constant discourse with her family
and other adults who, in her view, do not realise the consequences of climate change or take them seriously. Her aunt,
who works as a journalist, then decides to take her niece on a trip. Exciting projects from all over the world and
inspiring conversations with scientists, politicians and entrepreneurs are intended to inspire her and the viewers to
rethink. Due to their interest in EcoArt, the two women travel to Dreieich to visit the "Linfa" mural on the Biotest
campus and talk to Biotest's CEO, Peter Janssen, about the associated GoFuture sustainability initiative.
With this documentary, the makers want to open up a dialogue about the future of our society and address the
responsibility of each individual with regard to a more sustainable future. "We are very proud to be part of this
documentary with our GoFuture sustainability campaign and to be able to help give affected people new hope for a better
future," said Peter Janssen. "As a pharmaceutical company that uses donors' blood plasma as a natural resource for drug
production, we feel a tremendous responsibility towards both humanity and the environment, because the health of people
is inseparable from the health of the planet."
Future Seeds is now available in Germany, Austria, Switzerland, the United Kingdom, France, Spain, Italy, Hungary,
Turkey, Canada, Australia and in the United States. The access on Prime Video and the film title vary depending on the
country and language version. Access Prime Video here.

For more information about the GoFuture campaign, visit: gofuture.biotest.com


About Biotest
Biotest is a provider of biological therapeutics derived from human plasma. With a value added chain that extends from
pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical
immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors
and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest
has more than 2,400 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime
Standard on the German stock exchange. Since May 2022, Biotest has been a part of the Grifols Group, based in
Barcelona, Spain (www.grifols.com).

Biotest AG will now also be publishing official press releases via X. You can find us at: https://twitter.com/BiotestAG


IR contact
Dr Monika Baumann (Buttkereit)
Phone: +49-6103-801-4406
Mail: ir@biotest.com

PR contact
Dirk Neumüller
Phone: +49-6103-801-269
Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings,
financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans,
estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that
could result in significant deviation of actual developments from expected developments. The forward-looking statements
are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes
no obligation to do so.


2024-06-24 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.eqs-news.com  
Language:     English 
Company:      Biotest AG 

Landsteinerstraße 5
63303 Dreieich
Germany

Phone:        0 61 03 - 8 01-0 
Fax:          0 61 03 - 8 01-150 
E-mail:       ir@biotest.com 
Internet:     www.biotest.de 
ISIN:         DE0005227235, DE0005227201 
WKN:          522723, 522720 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 

Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1931603

End of News EQS News Service
===
1931603 2024-06-24 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1931603&application_name=news

END) Dow Jones Newswires

June 24, 2024 08:00 ET (12:00 GMT)